Chinese researchers said in a study they conducted that a booster dose produced by the Chinese company Sinopharm of its vaccine against the Corona virus was much weaker in the resistance of the mutated Omicron than the virus, although they added that the effectiveness of the vaccine against Omicron is still unclear.
The study was conducted by researchers from Shanghai Jiao Tong University and a laboratory in Shanghai that specializes in infectious respiratory diseases, and investigated the effect of a booster dose of the Sinovark vaccine against an older strain of the virus from the Chinese city of Wuhan.
And the research, published on Saturday, stated that the activity of antibodies generated by the booster dose to neutralize the virus showed a decrease of 20.1 times compared to the effect of the dose on the Wuhan strain.
Sinopharma did not immediately respond to a request for comment.
The study analyzed samples from 292 health care workers who received a third dose between eight and nine months after the second dose.